Engitix adds $25m to fuel ECM-driven push in cancer and fibrosis
UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will support preclinical development of extracellular matrix-targeted programs in solid tumors and fibrotic diseases.
The company is developing therapies aimed at the extracellular matrix (ECM), a non-cellular network that shapes tissue structure and signaling and is increasingly linked to disease progression. Engitix believes targeting the ECM could open new routes to treating cancers and fibrosis that resist conventional, cell-focused approaches.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze